Relief says Nexodyn's trial for rare skin disorder gets IRB approval

Sep. 22, 2022 6:49 AM ETRelief Therapeutics Holding AG (RLFTF), RLFTDBy: Ravikash, SA News Editor1 Comment

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Analysing Test Samples. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff

Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) said that an investigator initiated trial of Nexodyn for a rare skin disorders called Epidermolysis Bullosa (EB) received IRB approval and will shortly begin enrolling participants.

The Swiss company noted that the trial represents an important step in the clinical development of its own drug APR-TD011, a pharmaceutical grade hypochlorous acid topical spray being evaluated for decolonization, symptom alleviation and healing of EB wounds.

Nexodyn is engineered by the TEHCLO technology and is a highly pure and stabilized hypochlorous acid is presented as a self-administered sprayable solution for cleansing wounds. Meanwhile, APR-TD011, which is made with the company's TECHLO technology, is a GMP grade pharmaceutical hypochlorous acid wound solution being developed specifically for EB, Relief said in a Sept. 22 press release.

"This proof-of-concept clinical trial, to be conducted in 15 participants over a 12-week study period, will be most valuable for the swift, effective and efficient execution of Relief's clinical development plan for APR-TD011," said Relief's Chief Medical Officer Nermeen Varawalla.

The study will be conducted at at the Ann & Robert H. Lurie Children's Hospital of Chicago.

EB is a group of rare inherited skin disorders which cause the skin to become very fragile and any trauma or friction can cause painful blisters.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.